ADMS News and Press, Adamas Pharmaceuticals Inc. From 01/30/21

Adamas has become much less exciting the last few years with sales of GOCOVRI slowing in its second year. They decided to give up on attempting to treat the walking speed in those with Multiple Sclerosis with GOCOVRI after lackluster results. Hope remains with a new CEO, Neil McFa...

Gainers: [[ADMS]] +13.2%. [[CTMX]] +5.6%. [[MSTR]] +4.9%. [[FARM]] +4.8%. [[NERV]] +4%.Losers: [[CATB]] -10.6%. [[PTVE]] -8%. [[MRVI]] -3.9%. [[ZI]] -3.8%. [[ICON]] -3.5%. For further details see: MSTR, ZI, ADMS and CATB among after-hours movers

Gainers: [[BBBY]] +17.7%. [[IMMP]] +15.8%. [[FHTX]] +7.6%. [[TLSA]] +6.8%. [[ADMS]] +6.8%.Losers: [[TTOO]] -20.3%. [[VIR]] -17.0%. [[GRTX]] -16.6%. [[AGIO]] -8.4%. [[WMG]] -7.7%. For further details see: BBBY, IMMP, TTOO and VIR among after-hours movers

Adamas Pharmaceuticals (ADMS) expects total revenue for Q4 to be $20.8M and $74.2M for FY 2020.Product sales of GOCOVRI is expected to be $19.8M for Q4, an increase of 21% from same quarter prior year and $71.2M for FY 2020.“I am proud of our team’s resilience, ab...

-- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI ® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 -- -- Total prescriptio...

EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executiv...

EMERYVILLE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of the settlement of paten...

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company&#x...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Adamas Pharmaceuticals (ADMS) inks an agreement with Healthcare Royalty Partners amending its royalty-backed loan agreement. Key changes:Revised to provide for repayment from a royalty on OSMOLEX ER (amantadine) on the same terms as, and in addition to, the royalty for GOCOVRI ...